Identification of Constituents of Human Neutrophil Azurophil Granules That Mediate Fungistasis against *Histoplasma capsulatum*

SIMON L. NEWMAN,1* LISA GOOTEE,1 JOELLE E. GABAY,2 AND MICHAEL E. SELSTED3

Department of Medicine, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 452671; the Beatrice and Samuel A. Seaver Laboratory, Division of Hematology-Oncology, Department of Medicine, Cornell University Medical College, New York, New York 100212; and Department of Pathology, University of California—Irvine, College of Medicine, Irvine, California 926973

Received 6 March 2000/Returned for modification 11 April 2000/Accepted 29 June 2000

Previously we demonstrated that human neutrophils mediate potent and long-lasting fungistasis against *Histoplasma capsulatum* yeasts and that all of the fungistatic activity resides in the azurophil granules. In the present study, specific azurophil granule constituents with fungistatic activity were identified by incubation with *H. capsulatum* yeasts for 24 h and by quantifying the subsequent growth of yeasts via the incorporation of [3H]leucine. Human neutrophil defensins HNP-1, HNP-2, and HNP-3 inhibited the growth of *H. capsulatum* yeasts in a concentration-dependent manner with maximum inhibition at 8 μg/ml. At a concentration of 4 μg/ml, all possible paired combinations of defensins exhibited additive fungistatic activity against *H. capsulatum* yeasts. Cathepsin G and bactericidal-permeability-increasing protein (BPI) also mediated fungistasis against *H. capsulatum* in a concentration-dependent manner. The fungistatic activities of combinations of cathepsin G and BPI were additive, as were those of combinations of cathepsin G or BPI with HNP-1, HNP-2, and HNP-3. Lysozyme and elastase exhibited modest antifungal activity, and azurocidin and proteinase 3 exhibited no significant fungistasis against *H. capsulatum* yeasts. Thus, defensins, cathepsin G, and BPI are the major anti-*H. capsulatum* effector molecules in the azurophil granules of human neutrophils.

*Histoplasma capsulatum* is a dimorphic fungal pathogen of worldwide importance that causes a broad spectrum of disease activity. The course of *H. capsulatum* infection is mild in most immunocompetent individuals, but progressive disseminated infections occur in individuals immunocompromised by hematologic malignancies (6, 25, 30) or cytotoxic therapy (16, 32, 33) or in individuals infected with human immunodeficiency virus (15, 20, 31).

Infection with *H. capsulatum* is acquired by inhalation of microconidia into the terminal bronchioles and alveoli of the lung. Inhaled microconidia subsequently convert into yeasts that are responsible for the pathogenesis of histoplasmosis (17). *H. capsulatum* yeasts are phagocytized by alveolar macrophages (Mφ), within which they multiply (2, 7). Dividing yeasts destroy the alveolar Mφ, and subsequently the yeasts are ingested by other resident alveolar Mφ and by inflammatory phagocytes recruited to the locus of infection. Repetition of this cycle results in spread of infection to hilar lymph nodes and to other organs during the acute phase of primary histoplasmosis. Subsequently, the maturation of specific cell-mediated immunity against *H. capsulatum* activates Mφ to halt yeast proliferation with gradual resolution of the disease process in immunocompetent hosts (7, 22).

The role of polymorphonuclear neutrophils (PMNs) in the cell-mediated immune response against *H. capsulatum* is unclear (7). However, even the earliest studies in a murine model of histoplasmosis described PMNs as being the predominant inflammatory cell type in the lungs during the first 36 h after intranasal inoculation with *H. capsulatum* macroconidia. In these studies the PMNs were not observed to phagocytose the macroconidia, and the few yeasts that were present at 36 h were found only within Mφ (24). Baughman et al. (2) observed an intense PMN response in the lung at 1 week of infection after intranasal inoculation of C57BL/6 mice with yeasts of *H. capsulatum* strain G217B. By the second week, PMNs were largely supplanted by mononuclear cells characteristic of a granulomatous inflammatory response. Thus, these in vivo observations suggest that PMNs may play a role in host defense against *H. capsulatum* at early times postinfection.

Previously (23), we demonstrated that human PMNs mediate potent and long-lasting fungistatic activity against *H. capsulatum* yeasts and that all of the fungistatic activity is contained in the azurophil granules. The present study was designed to (i) identify which constituents of neutrophil azurophil granules mediate fungistasis against *H. capsulatum* yeasts and (ii) determine if there is additive or synergistic activity between various components. The data presented demonstrate that the defensins HNP-1, HNP-2, and HNP-3, as well as cathepsin G and bactericidal-permeability-increasing protein (BPI), mediate the majority of the fungistasis that is derived from PMN azurophil granules.

**MATERIALS AND METHODS**

**Yeasts.** *H. capsulatum* strain G217B was maintained as previously described (21). Yeasts were grown in HMM medium (36) at 37°C with orbital shaking at 150 rpm. After 2 days, log-phase yeasts were harvested by centrifugation, washed three times in Hank’s balanced salt solution containing 20 mM HEPES and 0.25% bovine serum albumin, and resuspended to 50 ml in the same buffer. Large aggregates were removed by centrifugation at 200 × g for 5 min at 4°C. The top 5 ml was removed, and the single-cell suspension obtained was standardized to 5 × 10⁸/ml in HMM medium diluted 1/25 in 10 mM phosphate buffer (pH 6.0 or 7.0 as designated below).

**Azurophil granule components.** Lysozyme, elastase, and cathepsin G were purchased from Sigma Chemical Co., St. Louis, Mo. BPI was a gift from Incyte Pharmaceuticals, Palo Alto, Calif. Human neutrophil defensins HNP-1, HNP-2,
Human neutrophil defensins mediate fungistasis against *H. capsulatum*. In initial studies, various concentrations of HNP-1, HNP-2, and HNP-3 were incubated with *H. capsulatum* yeasts for 24 h at 37°C. The data in Fig. 1 show that all three defensins mediated a concentration-dependent inhibition of the growth of *H. capsulatum* yeasts and that HNP-2 had the greatest inhibitory activity at all concentrations tested.

**RESULTS**

**TABLE 1. Additive effects of cathepsin G and BPI in inhibiting the growth of *H. capsulatum* yeasts**

<table>
<thead>
<tr>
<th>Conc’n (µg/ml) of:</th>
<th>% Inhibition of growth$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cathepsin G</td>
</tr>
<tr>
<td>0.1</td>
<td>13.4 ± 4.6</td>
</tr>
<tr>
<td>0.5</td>
<td>23.3 ± 7.4</td>
</tr>
<tr>
<td>0.1</td>
<td>39.0 ± 8.1</td>
</tr>
<tr>
<td>0.1</td>
<td>43.4 ± 5.8</td>
</tr>
</tbody>
</table>

$^a$ *H. capsulatum* yeasts ($5 \times 10^7$) were incubated with cathepsin G, BPI, or both for 24 h at 37°C. The yeasts were pulsed with [³H]leucine for an additional 24 h to quantitate the growth of the remaining viable yeasts.

$^b$ Mean ± SEM; $n = 4$. 

and HNP-3 and azurocidin and proteinase 3 were purified as described previously (4, 10, 12, 27). All azurophil granule components were diluted in 10 mM citrate phosphate buffer (pH 7.0), except for cathepsin G and BPI, which were at pH 6.0. These pHs were chosen for optimum activity of the different granule components in the fungistasis assay as determined in preliminary experiments.

**Quantitation of fungistatic activity against *H. capsulatum* yeasts.** The fungistatic activity of the various azurophil granule components was quantified by the incorporation of [³H]leucine into remaining viable yeasts (23). Viable *H. capsulatum* yeasts ($5 \times 10^8$ in 0.1 ml) were added to the wells of a 96-well tissue culture plate and were incubated with 0.1 ml of various concentrations of individual components of neutrophil azurophil granules. Control wells contained *H. capsulatum* yeasts added to 0.1 ml of citrate phosphate buffer. After culture for 24 h at 37°C, the plates were centrifuged at 700 × g, the supernatants were removed, and the yeasts were incubated for a further 24 h with 1 µCi of [³H]leucine in 50 µl of distilled water containing 10% yeast nitrogen broth. Numbers of cpm from control wells containing yeasts only were compared to those from wells containing yeasts cultured in the presence of defensins, and the percent inhibition of growth was calculated. The data are means ± SEMs ($n = 3$). The mean ± SEM cpm in control wells was 45,182 ± 8,697.

**RESULTS**

**FIG. 1. Concentration-dependent inhibition of the growth of *H. capsulatum* yeasts by HNP-1, -2, and -3. *H. capsulatum* yeasts ($5 \times 10^7$ cells) were incubated with various concentrations of defensins for 24 h at 37°C. At the end of the incubation period, the plates were centrifuged, the supernatants were removed, and the yeasts were incubated for a further 24 h with 1 µCi of [³H]leucine in 50 µl of distilled water containing 10% yeast nitrogen broth. Numbers of cpm from control wells containing yeasts only were compared to those from wells containing yeasts cultured in the presence of defensins, and the percent inhibition of growth was calculated. The data are means ± SEMs ($n = 3$). The mean ± SEM cpm in control wells was 45,182 ± 8,697.**

**FIG. 2. Inhibition of the growth of *H. capsulatum* yeasts by combinations of defensins. The procedure was as described in the legend to Fig. 1. Defensins were aspirated through a 27-gauge needle, and 50 µl of [³H]leucine (specific activity, 153 Ci/mmol; New England Nuclear, Boston, Mass.) in sterile water (1.0 µCi) and 5 µl of a 10× yeast nitrogen broth (Difco Laboratories, Detroit, Mich.) were added to each well. After further incubation for 24 h at 37°C, 50 µl of l-leucine (10 mg/ml) and 50 µl of sodium hypochlorite were added to each well. The contents of the wells were harvested onto glass fiber filters using an automated harvester (Skatron, Sterling, Va.). The filters were placed into scintillation vials, the scintillation cocktail was added, and the vials were counted on a Beckman LS 7000 liquid scintillation spectrometer (Beckman Instruments, Inc., Fullerton, Calif.). As there was considerable variation in the counts per minute (cpm) obtained from yeasts multiplying in controls containing only medium, the data are presented as the means ± standard errors of the mean (SEMs) of percent inhibition, which is defined as 1 – (cpm in experimental wells/cpm in control wells) × 100. All experimental points were performed in triplicate, and all experiments were performed at least three times.**

**CATHEPSIN G BPI**

**FIG. 3. Concentration-dependent inhibition of the growth of *H. capsulatum* yeasts by cathepsin G and BPI. The procedure was as described in the legend to Fig. 1. The data are means ± SEMs of five experiments with cathepsin G and three experiments with BPI.**

**Mean ± SEM; $n = 4$.**

**TABLE 1. Additive effects of cathepsin G and BPI in inhibiting the growth of *H. capsulatum* yeasts**

<table>
<thead>
<tr>
<th>Conc’n (µg/ml) of:</th>
<th>% Inhibition of growth$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cathepsin G</td>
</tr>
<tr>
<td>0.1</td>
<td>13.4 ± 4.6</td>
</tr>
<tr>
<td>0.5</td>
<td>23.3 ± 7.4</td>
</tr>
<tr>
<td>0.1</td>
<td>39.0 ± 8.1</td>
</tr>
<tr>
<td>0.1</td>
<td>43.4 ± 5.8</td>
</tr>
</tbody>
</table>

$^a$ *H. capsulatum* yeasts ($5 \times 10^7$) were incubated with cathepsin G, BPI, or both for 24 h at 37°C. The yeasts were pulsed with [³H]leucine for an additional 24 h to quantitate the growth of the remaining viable yeasts.

$^b$ Mean ± SEM; $n = 4$.
Next, defensins were incubated with *H. capsulatum* yeasts for 24 h either singly or in paired combinations at 4 μg/ml. All combinations of defensins demonstrated essentially an additive capacity to inhibit the replication of *H. capsulatum* yeasts (Fig. 2).

Cathepsin G and BPI mediate fungistasis against *H. capsulatum*. As in the defensin experiments, various concentrations of cathepsin G and BPI were incubated with *H. capsulatum* yeasts for 24 h. Both BPI and cathepsin G inhibited the growth of yeasts in a concentration-dependent manner over a 4-log range, and their inhibitory activity was equivalent at all concentrations tested (Fig. 3). When studied in combination, the inhibitory activities of cathepsin G and BPI were additive (Table 1). In addition, BPI mediated fungistatic activity against *H. capsulatum* over a wide range of pH (Fig. 4). Only at pH 4 was BPI inactive. Similar results were obtained with cathepsin G (data not shown). Finally, in another series of experiments, it was demonstrated that the inhibitory activities of combinations of cathepsin G or BPI with either HNP-1, HNP-2, or HNP-3 were additive (Fig. 5).

Lysozyme and elastase but not azurocidin and proteinase 3 have modest antifungal activity against *H. capsulatum* yeasts. Incubation of various concentrations of lysozyme and elastase for 24 h with *H. capsulatum* yielded modest but not statistically significant inhibition of yeast replication (Table 2). In contrast, coculture of yeasts with azurocidin and proteinase 3 actually led to enhanced growth of *H. capsulatum* yeasts (Table 3). Various combinations of these azurophil components did not result in enhanced anti-*Histoplasma* activity, nor did they enhance the activity of defensins, cathepsin G, or BPI (data not shown).

![FIG. 4. The fungistatic activity of BPI occurs over a wide range of pH. The procedure was as described in the legend to Fig. 1 except that BPI was diluted in 10 mM citrate-phosphate buffer of various pHs. The media containing the yeasts also were at various pHs. The data are means ± SEMs (n = 4).](image)

![FIG. 5. Additive effects of cathepsin G or BPI and defensins in inhibiting the growth of *H. capsulatum* yeasts. The procedure was as described in the legend to Fig. 1. Cathepsin G was used at 0.1 μg/ml, BPI at 1 μg/ml, and defensins at 4 μg/ml. The data are means ± SEMs (n = 3–4). There was no statistical significance between any of the groups by analysis of variance.](image)

### Table 2. Inhibition of the growth of *H. capsulatum* yeasts by lysozyme and elastase

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Conc (μg/ml)</th>
<th>% Inhibition of growtha</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysozyme</td>
<td>1</td>
<td>16 ± 4</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>20 ± 5</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>36 ± 8</td>
</tr>
<tr>
<td>Elastase</td>
<td>1</td>
<td>17 ± 6</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>22 ± 8</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>25 ± 8</td>
</tr>
</tbody>
</table>

*H. capsulatum* yeasts (5 × 10⁴) were incubated with various concentrations of lysozyme and elastase for 24 h at 37°C. The yeasts then were pulsed with [³H]leucine for an additional 24 h to quantitate the growth of the remaining yeasts.

a Mean ± SEM (n = 10 for lysozyme and 6 for elastase). The data were not statistically significantly different from the controls (Student’s t test).
TABLE 3. Azurocidin and proteinase 3 do not inhibit the growth of *H. capsulatum* yeasts

| Reagent   | Conc (μg/ml) | % Inhibition of growth
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Azurocidin</td>
<td></td>
<td>−38 ± 34</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>−14 ± 30</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>−23 ± 35</td>
</tr>
<tr>
<td>Proteinase 3</td>
<td>0.1</td>
<td>−47 ± 32</td>
</tr>
<tr>
<td></td>
<td>0.5</td>
<td>−40 ± 30</td>
</tr>
<tr>
<td></td>
<td>1.0</td>
<td>−33 ± 36</td>
</tr>
</tbody>
</table>

*H. capsulatum* yeasts (5 × 10⁵) were incubated with various concentrations of azurocidin and proteinase 3 for 24 h at 37°C. The yeasts then were pulsed with [¹³C]leucine for an additional 24 h to quantitate the growth of the remaining yeasts.

Mean ± SEM (n = 7). The minus sign indicates that there was increased growth compared to yeasts cultured in control medium.

**DISCUSSION**

In exploring a possible role for neutrophils in host defense against *H. capsulatum*, we initially demonstrated that human PMNs bind unopsonized yeasts via CD18 as do human monocytes and Mφ (3, 21). Unlike Mφ, PMNs phagocytose few unopsonized yeasts. However, phagocytosis is significantly enhanced by heat-labile and heat-stable serum opsonins. Most interesting is the fact that although the phagocytosis of opsonized *H. capsulatum* yeasts stimulates a potent respiratory burst, superoxide anion (O₂⁻) is trapped intracellularly and not released into the extracellular milieu (26). Thus, we were surprised when subsequent studies revealed that the potent and long-lasting fungistatic activity that neutrophils mediate against *H. capsulatum* is not mediated by toxic oxygen metabolites but that all of the antifungal activity resided in the azurophil granules (23).

Human neutrophil azurophil granules contain two families of antimicrobial proteins, defensins and serprocidins, each with four members, and two antimicrobial proteins with unique primary structures, lysozyme and BPI (9, 11, 34). These azurophil granule proteins have been found to have a broad spectrum of antimicrobial activity against gram-negative and gram-positive bacteria, protozoans, enveloped viruses, and fungi, including *Cryptococcus neoformans*, *Candida albicans*, *Aspergillus fumigatus*, and *Rhizopus oryzae*.

HNPs are basic peptides that are 29 to 30 amino acids in length and contain three characteristic intramolecular disulfide bonds. HNP-1, HNP-2, and HNP-3, all of which mediate a concentration-dependent fungistasis against *H. capsulatum* yeasts, differ only in a single N-terminal amino acid. The peptides have a cyclic structure with spatial segregation of charged and hydrophobic residues. This amphiphilic structure may equip defensins for insertion into the phospholipid membrane of their target organism (27, 34, 35). Thus, the mechanism by which defensins might inhibit the replication of *H. capsulatum* yeasts is unclear, particularly because of its thick cell wall. However, as microorganisms may encounter defensin concentrations as high as 10 mg/ml (28), the observed fungistatic activity of defensins against *H. capsulatum* yeasts is well within the physiologic range.

The second major family of azurophil granule antimicrobial proteins, the serprocidins, consists of azurocidin, cathepsin G, elastase, and proteinase 3. Serprocidins are cationic glycoproteins of 25 to 29 kDa that exhibit considerable homology with serine proteases. Serprocidins are relatively abundant in PMNs (1 to 2 μg/10⁸ PMNs) and also demonstrate a broad spectrum of antimicrobial activity against gram-positive and gram-negative bacteria and fungi (9). Of the four members, only cathepsin G was found to inhibit the growth of *H. capsulatum* yeasts, and cathepsin G activity was additive in its inhibitory activity when mixed with defensins HNP-1, -2, and -3. Cathepsin G is a neutral protease of molecular mass 29 to 31 kDa (14) and has been reported to kill *Neisseria gonorrhoea* (29) and *Listeria monocytogenes* (1) by a nonenzymatic mechanism and to kill microorganisms that cause dental caries by both enzymatic and nonenzymatic mechanisms (19). Cathepsin G also can synergize with azurocidin in killing the oral microorganism *Capnocytophaga sputigena* (18).

The most unexpected results were obtained with BPI. BPI is a major component of the azurophil granules of PMNs and is found only in myeloid cells. BPI has a molecular mass of 50 to 60 kDa and contains a highly cationic, lysine-rich amino-terminal half and a very hydrophobic, much less charged, carboxy-terminal half (13). BPI has a strong affinity for lipopolysaccharide (LPS), and, therefore, its cytotoxic activity is directed almost exclusively to gram-negative bacteria. Indeed, the susceptibility of gram-negative bacteria appears to be determined primarily by the structure of the envelope LPS, specifically the length of the polysaccharide chains (8). However, despite the fact that *H. capsulatum* yeasts do not contain LPS, BPI inhibited the growth of yeasts in a concentration-dependent manner. Furthermore, the anti-*Histoplasma* activity of BPI was additive when BPI was mixed with cathepsin G or any of the three defensins. It is unclear what BPI might recognize on the surface of the yeasts to mediate its inhibitory effects.

While both our previous study (23) and the current study have demonstrated potent growth-inhibitory activity against *H. capsulatum* yeasts by whole PMNs and azurophil granule constituents, we have not actually quantified killing of the fungus. However, overall the data suggest that many of the yeasts are being killed. Thus, when neutrophils and yeasts are cocultured at a ratio of 50:1, no external yeasts are observed until after 6 days of culture, at which time most of the PMNs have disintegrated (23). In addition, in the current study, we observed that yeasts “shrunk” to small pinpoints during the 24 h of culture with defensins, cathepsin G, or BPI. Attempts to quantify the remaining viable yeasts by culture on HMM agar plates (36) were unsuccessful, whereas the CFU from control wells indicated that the yeasts had replicated over the 24-h incubation period. Since we can quantitatively plate 100 to 200 yeasts on these plates, these results suggest that perhaps greater than 95% of the yeasts may have been killed. Furthermore, when RAW 264.7 cells (a murine macrophage cell line) were transduced with cDNA encoding HNP-1, not only was the intracellular growth of *H. capsulatum* yeasts inhibited, but degraded ghost forms were frequently observed (5).

The potent fungistatic activity against *H. capsulatum* exhibited by human PMNs in vitro suggests that they may play an important role in host defense against *H. capsulatum* in vivo. Certainly PMNs may be capable of slowing the course of the infection, and, under certain circumstances, they may prevent dissemination of the yeasts from the lung. It also is possible that PMNs may damage the yeasts in such a manner as to render them vulnerable to inflammatory macrophages. Thus, inflammatory macrophages may phagocytose yeast-containing neutrophils and subsequently kill the partially damaged yeasts. Either or both of these postulated mechanisms of defense involving neutrophils during the early phase of the inflammatory response to *H. capsulatum* may explain, at least in part, the fact that a substantial percentage of pulmonary infections by this organism are subclinical and self-limiting.
ACKNOWLEDGMENTS

This work was supported by Public Health Service grants AI-32368, AI-37639, HL-55948, and AI-22931 from the National Institutes of Health.

We thank Marian Marra, Incyte Pharmaceuticals, for the generous gift of BPI.

REFERENCES


Editor: J. M. Mansfield